Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback